Zoledronic Acid (CPB 0524, reviewed 2026-02-12)

By 2026-02-12, billing and prior authorization teams must: (1) Review and update Aetna authorization protocols to align with specific medical necessity criteria for zoledronic acid 5mg (osteoporosis indications, glucocorticoid-induced osteoporosis, Paget's disease, prostate cancer ADT-related bone loss) and 4mg (bone metastases, breast cancer, hypercalcemia, multiple myeloma, Langerhans cell histocytosis, systemic mastocytosis); (2) Update billing system rules to flag claims requiring documentation of T-score, FRAX probability scores, fragility fracture history, or specific treatment indications before submission; (3) Implement continuation therapy validation requiring evidence of clinical benefit (T-score improvement/stabilization) for authorizations beyond 24 months; (4) Add contraindication checks for creatinine clearance <35 mL/min and acute renal impairment in billing software; (5) Train prior authorization staff on the distinction between approved indications and experimental uses (ankylosing spondylitis, aortic valve stenosis, aseptic necrosis, CRMO, etc.) to prevent denials; (6) Update provider encounter forms and order entry templates to capture required clinical data (baseline T-score, FRAX score, fracture history, glucocorticoid dose and duration, cancer type and treatment regimen). Failure to align with these criteria will result in prior authorization denials and claim rejections for non-compliant requests.